Full text not available from this repository.
Allergen-specific immunotherapy (SIT) in its various application forms represents the main treatment approach of IgE-mediated allergic diseases in adults and children. Despite this clear recommendation, many particularities of products, patient characteristics, and product availability in different countries hamper the use of allergen-specific immunotherapy in particular in children. The frequently asked questions by parents, patients, and physicians are the backbone of this review. Thus, the potentials and limitations of allergen-specific immunotherapy in children and adolescents will be highlighted. IgE-mediated allergic diseases are affecting about 20% of the population. They manifest commonly early in life, and hence, the use of SIT should be considered also early in the course of the disease.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > Swiss Institute of Allergy and Asthma Research|
|DDC:||610 Medicine & health|
|Deposited On:||11 Mar 2012 14:48|
|Last Modified:||27 Nov 2013 21:44|
|Citations:||Web of Science®. Times cited: 1|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page